{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:28:28Z","timestamp":1791178108821,"version":"4.1.0"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2010,7,26]],"date-time":"2010-07-26T00:00:00Z","timestamp":1280102400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0011770","type":"journal-article","created":{"date-parts":[[2010,7,26]],"date-time":"2010-07-26T21:20:45Z","timestamp":1280179245000},"page":"e11770","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":31,"title":["PR1-Specific T Cells Are Associated with Unmaintained Cytogenetic Remission of Chronic Myelogenous Leukemia After Interferon Withdrawal"],"prefix":"10.1371","volume":"5","author":[{"given":"Shreya","family":"Kanodia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Wieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Talpaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gheath","family":"Alatrash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Clise-Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Molldrem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2010,7,26]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood.V62.3.689.689","article-title":"Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia.","volume":"62","author":"M Talpaz","year":"1983","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2141.1986.tb07576.x","article-title":"Chronic myelogenous leukaemia: haematological remissions with alpha interferon.","volume":"64","author":"M Talpaz","year":"1986","journal-title":"Br J Haematol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7326\/0003-4819-122-4-199502150-00003","article-title":"Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service.","volume":"122","author":"HM Kantarjian","year":"1995","journal-title":"Ann Intern Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","article-title":"Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.","volume":"98","author":"F Bonifazi","year":"2001","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2141.1999.01749.x","article-title":"Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics.","volume":"107","author":"S Branford","year":"1999","journal-title":"Br J Haematol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/sj.leu.2401053","article-title":"Does BCR-ABL genomic rearrangement persist in CML patients in complete remission after interferon alpha therapy?","volume":"12","author":"F Brizard","year":"1998","journal-title":"Leukemia"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1172\/JCI117473","article-title":"Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies.","volume":"94","author":"M Talpaz","year":"1994","journal-title":"J Clin Invest"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"28570","DOI":"10.1074\/jbc.M011685200","article-title":"The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells.","volume":"276","author":"IA Mayer","year":"2001","journal-title":"J Biol Chem"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.V95.2.404","article-title":"Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation.","volume":"95","author":"JC Chomel","year":"2000","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.","volume":"351","author":"CH Jamieson","year":"2004","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nm1007-1144","article-title":"Where lies the blame for resistance\u2014tumor or host?","volume":"13","author":"CL Sawyers","year":"2007","journal-title":"Nat Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/cncr.11223","article-title":"Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.","volume":"97","author":"HM Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1172\/JCI2366","article-title":"An in vitro model for cytogenetic conversion in CML. Interferon-alpha preferentially inhibits the outgrowth of malignant stem cells preserved in long-term culture.","volume":"102","author":"JJ Cornelissen","year":"1998","journal-title":"J Clin Invest"},{"key":"ref14","first-page":"237","article-title":"Interferon-alpha: mechanisms of action in chronic myelogenous leukemia in chronic phase.","volume":"40","author":"F Guilhot","year":"1998","journal-title":"Hematol Cell Ther"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1182\/blood.V90.7.2529","article-title":"Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units.","volume":"90","author":"J Molldrem","year":"1997","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/79526","article-title":"Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia.","volume":"6","author":"J Molldrem","year":"2000","journal-title":"Nat Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF01972395","article-title":"The polymorphonuclear leukocyte.","volume":"8","author":"M Baggiolini","year":"1978","journal-title":"Agents Actions"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1365-2141.1995.tb03297.x","article-title":"Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells.","volume":"89","author":"R Dengler","year":"1995","journal-title":"Br J Haematol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/0092-8674(89)90752-6","article-title":"Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells.","volume":"59","author":"D Bories","year":"1989","journal-title":"Cell"},{"key":"ref20","first-page":"47338","article-title":"Cleavage of p21waf1 by proteinase-3, a myeloid-specific serine protease, potentiates cell proliferation.","volume":"277","author":"V Witko-Sarsat","year":"2002"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood.V88.7.2450.bloodjournal8872450","article-title":"Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells.","volume":"88","author":"J Molldrem","year":"1996","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1182\/blood-2007-02-071738","article-title":"High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects.","volume":"110","author":"AS Yong","year":"2007","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood-2005-05-2155","article-title":"Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML.","volume":"107","author":"AS Yong","year":"2006","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1172\/JCI200316398","article-title":"Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells.","volume":"111","author":"JJ Molldrem","year":"2003","journal-title":"J Clin Invest"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1073\/pnas.93.9.4102","article-title":"Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy.","volume":"93","author":"MA Alexander-Miller","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1084\/jem.184.2.485","article-title":"Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL.","volume":"184","author":"MA Alexander-Miller","year":"1996","journal-title":"J Exp Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.4049\/jimmunol.162.4.2227","article-title":"Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.","volume":"162","author":"C Yee","year":"1999","journal-title":"J Immunol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"989","DOI":"10.4049\/jimmunol.162.2.989","article-title":"High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy.","volume":"162","author":"HJ Zeh 3rd","year":"1999","journal-title":"J Immunol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","article-title":"Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia.","volume":"28","author":"A Burchert","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/35065118","article-title":"Skewed maturation of memory HIV-specific CD8 T lymphocytes.","volume":"410","author":"P Champagne","year":"2001","journal-title":"Nature"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/intimm\/10.3.311","article-title":"CD8hi+CD57+ T lymphocytes are enriched in antigen-specific T cells capable of down-modulating cytotoxic activity.","volume":"10","author":"L Mollet","year":"1998","journal-title":"Int Immunol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.4049\/jimmunol.167.9.4838","article-title":"Viral infections induce abundant numbers of senescent CD8 T cells.","volume":"167","author":"D Voehringer","year":"2001","journal-title":"J Immunol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1182\/blood-2002-07-2103","article-title":"Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells.","volume":"101","author":"JM Brenchley","year":"2003","journal-title":"Blood"},{"key":"ref34","first-page":"2675","article-title":"A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia.","volume":"59","author":"J Molldrem","year":"1999","journal-title":"Cancer Res"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"8210","DOI":"10.4049\/jimmunol.174.12.8210","article-title":"Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy.","volume":"174","author":"M Gannage","year":"2005","journal-title":"J Immunol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/360264a0","article-title":"Lifespan of human lymphocyte subsets defined by CD45 isoforms.","volume":"360","author":"CA Michie","year":"1992","journal-title":"Nature"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1093\/intimm\/11.7.1027","article-title":"Evidence that human CD8+CD45RA+CD27- cells are induced by antigen and evolve through extensive rounds of division.","volume":"11","author":"D Hamann","year":"1999","journal-title":"Int Immunol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1084\/jem.187.9.1395","article-title":"Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo.","volume":"187","author":"MF Callan","year":"1998","journal-title":"J Exp Med"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/nm1326","article-title":"Host-reactive CD8+ memory stem cells in graft-versus-host disease.","volume":"11","author":"Y Zhang","year":"2005","journal-title":"Nat Med"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/blood-2003-03-0975","article-title":"Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.","volume":"103","author":"S Appel","year":"2004","journal-title":"Blood"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood-2004-07-2527","article-title":"Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner.","volume":"105","author":"R Seggewiss","year":"2005","journal-title":"Blood"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/14653240802317639","article-title":"Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update.","volume":"10","author":"R Seggewiss","year":"2008","journal-title":"Cytotherapy"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/sj.leu.2403401","article-title":"Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro.","volume":"18","author":"K Cwynarski","year":"2004","journal-title":"Leukemia"},{"key":"ref44","first-page":"1094","article-title":"Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo.","volume":"104","author":"AB Dietz","year":"2004"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/13684730210002319","article-title":"Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia.","volume":"7","author":"JM Aswald","year":"2002","journal-title":"Cytokines Cell Mol Ther"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/BF03006921","article-title":"Cytogenetic remissions induced by interferon alpha and imatinib mesylate are immunologically distinct in chronic myeloid leukemia.","volume":"86","author":"S Nakayama","year":"2007","journal-title":"Int J Hematol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0011770","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T09:58:16Z","timestamp":1685699896000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0011770"}},"subtitle":[],"editor":[{"given":"Derya","family":"Unutmaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,7,26]]},"references-count":46,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2010,7,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0011770","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,26]]}}}